An exploratory double-blind, placebo controlled, randomized, 12-week oral dose study to evaluate the effects of MK0736 on atherosclerotic disease biomarkers in lower extremity plaque excised from patients with peripheral arterial disease

Trial Profile

An exploratory double-blind, placebo controlled, randomized, 12-week oral dose study to evaluate the effects of MK0736 on atherosclerotic disease biomarkers in lower extremity plaque excised from patients with peripheral arterial disease

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

At a glance

  • Drugs MK 0736 (Primary)
  • Indications Atherosclerosis; Peripheral arterial disorders
  • Focus Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 25 Aug 2008 The expected completion date for this trial is now 1 Aug 2008.
    • 05 Aug 2008 Actual start date changed from Dec 2008 to Aug 2008 as reported by ClinicalTrials.gov.
    • 05 Aug 2008 Patient number amended from 130 to 15 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top